Tiprelestat is under clinical development by Tiakis BIOTECH and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tiprelestat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tiprelestat (Elafin) is under development for the treatment of inflammatory complications associated with post-operative esophageal carcinoma and transthoracic esophagectomy, ischemia-reperfusion injury, pulmonary arterial hypertension, ventilator-induced lung injury in premature babies, vascular damage, lung transplant, life-threatening infections and inflammation of cardiac muscle after coronary bypass operations and attenuation of severe disease progression of COVID-19. It is administered through intravenous and subcutaneous route. Elafin is a serine protease inhibitor. The drug candidate was also under development for kidney transplantation, lung transplant rejection and thromboembolic pulmonary hypertension.
Tiakis BIOTECH overview
tiakis BIOTECH (tiakis) formerly Proteo Biotech, a subsidiary of Proteo Inc, is developer and marketer of nature identical compounds for biological and medical research, and for use as pharmaceuticals. The company develops pharmaceuticals based on body’s immune system to fight inflammatory diseases. It provides product pipeline such as elafin, a soluble endogenous protein produced by the human body and acts as a natural inhibitor of tissue destroying enzymes. tiakis’s pre-clinical research areas includes pulmonary arterial hypertension, ventilator-induced injury of the immature lung in premature babies, chronic lung transplant rejection, vascular damages and life threatening infections. It offers services such as research and development, clinical development and preclinical research. tiakis is headquartered in Kiel, Schleswig-Holstein, Germany.
For a complete picture of Tiprelestat’s drug-specific PTSR and LoA scores, buy the report here.